Suppr超能文献

基于 Mayo 临床表型的基因检测预测评分在日本肥厚型心肌病患者中的验证研究。

A Validation Study of the Mayo Clinic Phenotype-Based Genetic Test Prediction Score for Japanese Patients With Hypertrophic Cardiomyopathy.

机构信息

Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University.

Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University.

出版信息

Circ J. 2021 Apr 23;85(5):669-674. doi: 10.1253/circj.CJ-20-0826. Epub 2021 Jan 23.

Abstract

BACKGROUND

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal-dominant disorder mainly caused by mutations in sarcomere genes. Recently, a phenotype-based genetic test prediction score for patients with HCM was introduced by Mayo Clinic. The genotype score was derived on the basis of the predictive effect of 6 clinical markers, and the total score was shown to be correlated with the yield of genetic testing. However, it has not been determined whether this prediction model is useful in Japanese HCM patients.

METHODS AND RESULTS

The utility of the Mayo Clinic HCM genotype predictor score in 209 Japanese unrelated patients with a clinical diagnosis of HCM who had undergone genetic testing for 6 sarcomere genes was assessed. Overall, 55 patients (26%) had pathogenic or likely pathogenic variants (60% being genotype-positive in familial cases). We divided the patients into 6 groups (groups with scores of from -1 to 5) according to the prediction score. The yields of genetic testing in the groups with scores of -1, 0, 1, 2, 3, 4, and 5 were 8%, 16%, 24%, 48%, 50%, 100%, and 89%, respectively, with an incremental increase in yield between each of the score subgroups (P<0.001).

CONCLUSIONS

The Mayo Clinic HCM genotype predictor score is useful for predicting a positive genetic test result in Japanese HCM Patients.

摘要

背景

肥厚型心肌病(HCM)是一种主要由肌节基因突变引起的常染色体显性遗传原发性心肌疾病。最近,梅奥诊所引入了一种基于表型的 HCM 患者遗传检测预测评分。基因型评分基于 6 个临床标志物的预测效果得出,总评分与遗传检测的检出率相关。然而,该预测模型在日本 HCM 患者中是否有用尚未确定。

方法和结果

评估了 209 例日本无亲缘关系的临床诊断为 HCM 并接受 6 个肌节基因遗传检测的患者中梅奥诊所 HCM 基因型预测评分的效用。总体而言,55 例患者(26%)存在致病性或可能致病性变异(家族病例中 60%为基因型阳性)。我们根据预测评分将患者分为 6 组(评分从-1 到 5)。评分分别为-1、0、1、2、3、4 和 5 的组的基因检测阳性率分别为 8%、16%、24%、48%、50%、100%和 89%,每组之间的阳性率呈递增趋势(P<0.001)。

结论

梅奥诊所 HCM 基因型预测评分可用于预测日本 HCM 患者的阳性基因检测结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验